Navigation Links
Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex

MELBOURNE, Australia, and MENLO PARK, California U.S.A. (May 21, 2007): ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) notes the publication of new clinical data relevant to the development strategy for Ceflatonin® (homoharringtonine). The paper "Targeted therapy and the T315I mutation in Philadelphia-positive leukemias" by researchers Simona Soverini and colleagues at the University of Bologna, Italy (Haematologica Volume 92, pages 401-404) offers insight into the growing therapeutic challenge presented by the T315I Bcr-Abl point mutation in patients with chronic myeloid leukemia (CML). The T315I Bcr-Abl mutation is associated with the development of resistance to tyrosine kinase inhibitor drugs such as imatinib (Gleevec®).

The paper describes the clinical progress of Gleevec-resistant CML patients who were treated with dasatinib (Sprycel®).

Key points of the publication are as follows:

• The study followed 45 Philadelphia-positive CML and acute lymphoblastic leukemia (ALL) patients who had failed Gleevec, and who were migrated to dasatinib therapy.

• Eight of the 45 patients (17.7%) had primary resistance to dasatinib, and showed no response. Seven of these 8 patients harboured the T315I point mutation.

• A further 13 patients (28.8%) acquired resistance to dasatinib after a median of 7 months, and seven (15.6%) of these patients were T315I positive.

• In summary the T315I mutation was associated with resistance to dasatinib in 31% of patients, and the total number of patients who were resistant to therapy was 46.7%.

• This incidence of T315I-associated resistance is higher than has previously been reported and reflects, in the words of Soverini et al., that the T315I mutation "is likely to become the prevalent mutation in those who fail to benefi
'"/>




Page: 1 2 3

Related medicine technology :

1. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
2. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
3. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent
4. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
5. Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies
6. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
7. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
8. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
9. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
10. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
11. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
Post Your Comments:
(Date:12/19/2014)... Mass. , Dec. 18, 2014  Decision Resources ... the United States will increase to ... will be primarily driven by expansion in the large ... energy devices will be increasingly adopted due to the ... Other key findings from Decision Resources Group,s ...
(Date:12/19/2014)... CITY, Kan. , Dec. 18, 2014 /PRNewswire/ ... PETX ), a biopharmaceutical company focused on the ... companion animals, today announced positive results from its ... innovative drug for treating pain in dogs with ... improvements in pain assessment scores that were statistically ...
(Date:12/17/2014)... 17, 2014 Revenue and earnings above ... research and development In the past 2013/14 fiscal ... two percent to EUR 4.287 billion (last year: EUR 4.190 ... percent to EUR 360 million. "Overall, 2013/14 was a successful ... Kaschke , President and CEO of Carl Zeiss AG. "Thanks ...
Breaking Medicine Technology:U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2
... 19 Reportlinker.com announces that a new market research ... Production and Market of Xylose in China ... overcapacity and the global financial crisis in Q4 2008, ... small manufacturers suspended or even stopped production due to ...
... YORK, Aug. 19 Reportlinker.com announces that a ... catalogue: Advances in Large Scale ... http://www.reportlinker.com/p0265199/Advances-in-Large-Scale-BioManufacturing-and-Scale-Up-Production-2nd-ED.html A ... of Biopharmaceutical Manufacturing. This new ASM study provides ...
Cached Medicine Technology:Reportlinker Adds Production and Market of Xylose in China 2Reportlinker Adds Production and Market of Xylose in China 3Reportlinker Adds Advances in Large Scale BioManufacturing and Scale-Up Production, 2nd ED 2Reportlinker Adds Advances in Large Scale BioManufacturing and Scale-Up Production, 2nd ED 3
(Date:12/19/2014)... (PRWEB) December 19, 2014 After a ... performer is again returning to the stage to entertain ... husband for concert performances, and the successful tour has ... originally announced. , Visit Ticketability.com for ... newly-announced Detroit shows at fair prices. , Music fans ...
(Date:12/19/2014)... News) -- A new study suggests a possible link ... flashes and night sweats -- and higher rates of ... common during menopause, affecting about 60 percent of women. ... menopause, since they then face a higher risk of ... who exhibit moderate or severe menopausal symptoms are more ...
(Date:12/19/2014)... News) -- Prostaglandin analogue eye drops -- a common ... of vision loss in patients with the eye disease, ... David Garway-Heath, of the Moorfields Eye Hospital and UCL ... than 500 people newly diagnosed with open-angle glaucoma -- ... of the leading causes of blindness. About 45 ...
(Date:12/17/2014)... December 17, 2014 This prestigious ... practices that have made outstanding and innovative contributions ... and progression of private practice physical therapy by ... Therapy Association. , On behalf of Performance Physical ... and CEO of Performance accepted the award at ...
(Date:12/17/2014)... Now in its second year, the ... the best in senior living and home care across ... communities and agencies that have received outstanding online feedback ... nearly 100,000 providers currently listed on SeniorAdvisor.com, only 879 ... Best of 2015 Awards are located all over the ...
Breaking Medicine News(10 mins):Health News:Garth Brooks Tickets for Joe Louis Arena: Ticketability.com Becomes a Popular Destination for Discount Tickets for Garth Brooks’ Detroit Concerts Set for February 27-28 2Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 3
... Reporter , THURSDAY, Jan. 5 (HealthDay News) -- Pediatric ... to lower the threshold for toxic lead exposure in ... and house paint, can permanently damage developing brains. ... Poisoning Prevention voted to recommend that the federal government ...
... of patients with mild-to-moderate asthma have persistently non-eosinophilic ... anti-inflammatory treatments, according to a new study. ... enrolled in nine clinical trials conducted by the ... eosinophils) was,found in only 36% of asthmatics not ...
... Mozes HealthDay Reporter , THURSDAY, Jan. 5 ... double their risk of developing a particularly advanced form ... large new European study suggests. The possible link ... (AMD), a significant cause of blindness in seniors. ...
... Proton therapy, a type of external beam radiation therapy, ... according to two new studies published in the January ... (Red Journal), the American Society for Radiation Oncology,s ... study, researchers at the University of Florida in Jacksonville, ...
... Jan. 5 (HealthDay News) -- Children and young adults ... for complications from the flu and should receive flu ... in Ohio in February 2011. Of the 130 ... young adults with neurological and neurodevelopmental conditions, 76 (58 ...
... cost paid for statins (drugs to lower cholesterol) in ... insurance is approximately 400 percent higher than comparable costs ... These findings, from the Boston University School of Medicine ... results of a comprehensive comparison of prescription drug costs ...
Cached Medicine News:Health News:Experts Endorse Lower Lead-Poisoning Threshold 2Health News:Experts Endorse Lower Lead-Poisoning Threshold 3Health News:A large subgroup of mild-to-moderate asthma is persistently non-eosinophilic 2Health News:Could Daily Aspirin Harm Seniors' Eyes? 2Health News:Could Daily Aspirin Harm Seniors' Eyes? 3Health News:Proton therapy effective prostate cancer treatment 2Health News:Study finds statin costs 400 percent higher in US compared to UK 2
... The BD Vacutainer® Safety-Lok™ Blood ... deliver patient care without compromising ... Safety-Lok™ Blood Collection Set with ... with one-handed activation. This product ...
... Omni-Flex System provides the capability ... the middle of surgery while ... the incision. The system is ... stable for large patients while ...
Standard general retractor system. Fully-adjustable to maintain a low profile in any approach and any patient. Blades can be stacked on top of each other in the operative site....
... System represents the most widely accepted ... wide array of retraction components provides ... system for multi-directional exposure of the ... available for specific procedures: IMA Kit ...
Medicine Products: